Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Actelion    ATLN   CH0010532478

ACTELION (ATLN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/16/2017 10/17/2017 10/18/2017 10/19/2017 10/20/2017 Date
271.25(c) 273(c) 273(c) 271.5(c) 273.75(c) Last
2 088 1 989 41 981 7 999 30 325 Volume
-0.18% +0.65% 0.00% -0.55% +0.83% Change
More quotes
Financials ( CHF)
Sales 2017 2 462 M
EBIT 2017 978 M
Net income 2017 -
Finance 2017 92,0 M
Yield 2017 -
Sales 2018 2 722 M
EBIT 2018 1 133 M
Net income 2018 -
Finance 2018 363 M
Yield 2018 -
P/E ratio 2017 31,83
P/E ratio 2018 27,43
EV / Sales2017 11,9x
EV / Sales2018 10,7x
Capitalization 29 381 M
More Financials
Company
Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with... 
More about the company
Surperformance© ratings of Actelion
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTELION
10/19 JOHNSON & JOHNSON : and Reports 2017 Third Quarter Results
10/18 JOHNSON & JOHNSON : Fades With Profit, Forecast
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17 JOHNSON & JOHNSON : tops Street 3Q forecasts, hikes forecast
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
09/14 ACTELION : Receives FDA Approval Of TRACLEER® bosentan For Use In Pediatric Pati..
09/08 ACTELION : receives FDA approval for 32mg Tracleer to treat paediatric PAH patie..
09/07 ACTELION : Receives fda approval of tracleer for use in pediatric patients with ..
09/07 JOHNSON & JOHNSON : Actelion Receives FDA Approval of Tracleer (bosentan) for Us..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on ACTELION 
ACTELION LTD - 2016
A good timing to anticipate a change in the trend
BUY
ACTELION LTD - 2016
The calm spell can be taken advantage of to put on new positions
BUY
More Strategies
Latest Tweets
10/18Hot Corner: Startups nach der Actelion-Rezeptur  
10/18Actelion : J&J Net Income Falls After Actelion Deal -- WSJ  
10/17Strong drug sales, Actelion buy power J&J's profit beat $JNJ #Earnings  
10/17Strong drug sales, Actelion buy power J&J's profit beat
5
10/17Strong drug sales, Actelion buy power J&J's profit beat  
More tweets
Qtime:61
News from SeekingAlpha
05/25 Cross-Border M&A Between U.S. And European Firms At 10-Year High
05/23 Actelion (ALIOF) Investor Presentation - Slideshow
05/19 Johnson & Johnson Lays Out Its Battle Plan
04/21 SNIPPET ROUNDUP : Tesaro's Parp Pricing Stumble And Asco Sneak Peek
04/18 JOHNSON & JOHNSON : No Surprises Here
Chart ACTELION
Duration : Period :
Actelion Technical Analysis Chart | ATLN | CH0010532478 | 4-Traders
Technical analysis trends ACTELION
Short TermMid-TermLong Term
TrendsBullishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 262  CHF
Spread / Average Target -4,2%
EPS Revisions
Managers
NameTitle
Ludo Ooms Chairman
Julian Bertschinger Director
Claudio Cescato Director
Pascal Hoorn Director
Andrea Ostinelli Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTELION24.15%29 840
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985